drugset / Trial / NCT04767828

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

NCT04767828

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study was to evaluate the progression time and efficacy of brain tumors in patients with brain metastases from HER2-positive breast cancer treated with Pyrrolidine and Capecitabine combined with brain radiotherapy.

Timeline

Start
2020-05-01
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 400 mg Oral
Subject Capecitabine Small molecule 800 mg/m2 Oral